Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4 −CD8 + T lymphocytes that are not lytic for the tumor

Abstract

In previous studies, the murine SaI (A/J derived, K k D d sarcoma was transfected with the allogeneic MHC class I H-2K b gene, and expressed high levels of H-2K b antigen. Contrary to expectations, the tumor cells expressing the alloantigen (SKB3.1M tumor cells) were not rejected by autologous A/J mice. Because these results contradict the laws of transplantation immunology, the present studies were undertaken to examine the immunogenicity of SKB3.1M and SaI cells in allogeneic hosts. Similar to SKB3.1M. SaI cells are lethal in some allogeneic strains, despite tumor-host MHC class I incompatibilities. Tumor challenges of SKB3.1M and SaI cells, however induce MHC class I-specific antibodies and CTL in both tumor-resistant and -susceptible hosts. Although the tumors induce specific CTL, tumor cells are not lysed in vitro by these CTL, suggesting that the tumor cells are resistant to CTL-mediated lysis. Since growth of these tumors does not follow the classical rules of allograft transplantation, and because the tumor is not susceptible to CTL-mediated lysis, we have used Winn assays to identify the effector lymphocyte(s) responsible for SaI rejection. Depletion studies demonstrate that the effector cell is a CD4 −CD8 + T lymphocyte. Collectively these studies suggest that the host's response to MHC class I alloantigens of SK-B3.1M and SaI cells does not determine tumor rejection, and that effector cells other than classically defined CTL, but with the CD4 −CD8 + phenotype, can mediate tumor-specific immunity.